Dimanche, 20 Mai 2018
Dernières nouvelles
Principale » BMO Capital Markets Begins Coverage on Akcea Therapeut (NASDAQ:AKCA)

BMO Capital Markets Begins Coverage on Akcea Therapeut (NASDAQ:AKCA)

12 Août 2017

The company has a consensus rating of Hold and a consensus target price of $47.13.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Tuesday, August 8th. The company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.13. The company had revenue of $104.15 million during the quarter, compared to analyst estimates of $93.29 million. The business's revenue for the quarter was up 170.7% compared to the same quarter previous year. During the same period in the prior year, the business earned ($0.47) earnings per share.

WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another domain, it was stolen and reposted in violation of USA & global trademark and copyright laws. The correct version of this report can be read at https://sportsperspectives.com/2017/08/11/akcea-therapeut-akca-research-coverage-started-at-cowen-and-company.html.

A number of other analysts have also recently commented on AKCA. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a "hold" rating to a "buy" rating and set a $59.00 target price on the stock in a report on Monday, July 31st. Needham maintained the shares of IONS in report on Friday, May 27 with "Buy" rating. They issued an outperform rating for the company.

Separately, Stifel Nicolaus initiated coverage on shares of Akcea Therapeut in a research report on Tuesday. Piper Jaffray Companies set a $51.00 target price on Ionis Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, May 10th. The stock's market capitalization is $6.49 billion. Three analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. Ionis Pharmaceuticals has an average rating of "Hold" and an average target price of $47.13.

Ionis Pharmaceuticals, Inc. has a 12-month low of $24.58 and a 12-month high of $60.01. Vanguard Group Inc. increased its stake in shares of Ionis Pharmaceuticals by 4.3% in the first quarter.

Winning Mega Millions Ticket Worth an Estimated $393M Sold in IL
According to lottery officials, a single, winning ticket in Friday's Mega Millions jackpot of almost $400 million. The ticket was sold at Nick's Barbecue in Palos, Heights, Illinois, just 30 minutes outside of Chicago.

Bb Biotech Ag bought 440,923 shares during the last quarter increasing its stake in Ionis Pharmaceuticals, Inc. Finally, Vanguard Group Inc. raised its position in Ionis Pharmaceuticals by 4.3% in the first quarter. Finally, Cheyne Capital Management UK LLP bought a new position in Ionis Pharmaceuticals during the second quarter worth approximately $249,000.

Hedge funds have recently modified their holdings of the stock. The value of the total investment in Ionis Pharmaceuticals, Inc. increased from $8,623,000 to $11,156,000 increasing 29.4% since the last quarter. In other words, EPS reveals how profitable a company is on a share owner basis. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

In other Ionis Pharmaceuticals news, SVP C Frank Bennett sold 10,000 shares of the company's stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $59.29, for a total transaction of $592,900.00. Following the transaction, the senior vice president now owns 25,041 shares in the company, valued at $1,484,680.89. The disclosure for this purchase can be found here. Motley Fool Wealth Management, LLC controls 342,329 shares with a value of $17,414,000.

About 2.02 million shares traded or 50.75% up from the average.

Ionis Pharmaceuticals, Inc.is engaged in discovering and developing ribonucleic acid -targeted therapeutics. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. In the Ionis Core segment, the Company is involved in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

BMO Capital Markets Begins Coverage on Akcea Therapeut (NASDAQ:AKCA)